Non-alcoholic steatohepatitis in liver transplant recipients diagnosed by serum cytokeratin 18 and transient elastography: A prospective study

Table 1 Characteristics of patients at study entry

	Whole cohort	Patients who developed NAFLD	Patients who developed NASH
	n = 40	n = 22	n = 17
Age (yr)	57.3 ± 8.5	55.5 ± 9.2	56.3 ± 7.9
Male (%)	28 (70)	18 (82)	14 (82)
Ethnicity (%)
Caucasian	32 (80)	19 (86)	15 (88)
Other (Asian, Black, Arab)	8 (20)	3 (14)	2 (11)
Etiology of liver disease (%)
NASH	21 (52.5)	13 (52)	12 (70)
HCC	9 (22.5)	2 (9)	2 (12)
HCV (excluding genotype 3)	8 (20)	6 (27)	3 (18)
Alcoholic liver disease	1 (2.5)	1 (4.5)	0
Other	1 (2.5)	0	0
BMI (kg/m2)	24.8 ± 4.6	26.2 ± 5.1	26.6 ± 4.5
BMI >25 (%)	18 (40)	14 (64)	12 (70)
Comorbidities (%)
Diabetes	14 (35)	9 (41)	8 (47)
Hypertension	15 (37.5)	7 (32)	8 (47)
Dyslipidemia	6 (15)	6 (27)	5 (29)
MELD-Na Score	< 9	< 9	< 9
Laboratory
AST (U/L)	27.6 ± 33	31.8 ± 41.2	34.5 ± 45.1
ALT (U/L)	32.8 ± 42.8	37.6 ± 52.6	40.6 ± 57.7
GGT (U/L)	177.5 ± 256.6	177.7 ± 271.4	188.1 ± 297.6
Bilirubin (µmol/L)	17 ± 15.9	18.2 ± 17.3	18 ± 18.2
INR	1.25 ± 1.39	1.05 ± 0.12	1.04 ± 1.3
Albumin (g/L)	39.6 ± 3.69	38.7 ± 4.3	39.4 ± 3.9
Platelets (109/L)	172.3 ± 86.9	185 ± 92.5	170.5 ± 93.6

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMI: Body mass index; GGT: Gamma-glutamyl transpeptidase; HCV: Hepatitis C virus; HCC: Hepatocellular carcinoma; INR: International normalized ratio; MELD-Na: Model for end stage liver disease-sodium; NAFLD: Nonalcoholic fatty liver disease; NASH: Nonalcoholic steatohepatitis.